Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
CA14161Y2006
Fri, 13.08.2021
Cardiol Therapeutics
Cardiol Therapeutics successful NASDAQ listing
NASDAQ Capital Market LLC has granted Cardiol final approval to list its
common shares on NASDAQ. On August 10, 2021, the Company's shares started
trading under the ticker 'CRDL'.
David Elsley, President & CEO of Cardiol Therapeutics, said, 'Listing on
NASDAQ is a major milestone for our Compa [ … ]
Wed, 23.06.2021
Cardiol Therapeutics
One Product in two formulations, heart disease treatments in the making
Cardiol Therapeutics provides leadership in therapeutic trials using
Cannabidiol to take advantage of major opportunities in inflammatory heart
disease.
The company has an exclusive manufacturing agreement for a Cannabidiol
pharmaceutical formulation which is highly concen [ … ]
Thu, 22.04.2021
Cardiol Therapeutics
The Company announced topline results from its Phase I Single and Multiple
Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a
pharmaceutically produced oral cannabidiol formulation being developed for
the treatment of acute and chronic inflammation associated with heart
disease. These results positively support Cardiol Therapeutics' pr [ … ]
Mon, 29.03.2021
Cardiol Therapeutics
GBC Research Watchlist: Cardiol Therapeutics Inc.
'The right moment to participate in this exciting growth story'
Cortalex - The purest form of CBD, no THC. It matters.
For many patient segments, CBD medication can be linked to the possibility
of becoming intoxicated by THC. For children, young adults under 25,
workers that cannot be intoxic [ … ]
